Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AHMED Z OBEIDAT

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1184069627
CMS profile
1382667
Location
MILWAUKEE, WI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$211,659.26

202 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Alexion Pharmaceuticals, Inc. $88,749.72 83
Biogen, Inc. $72,188.53 61
Novartis Pharmaceuticals Corporation $20,611.07 28
GENZYME CORPORATION $17,900.78 17
Celgene Corporation $7,513.24 8
Genentech USA, Inc. $4,581.33 4
Medtronic USA, Inc. $114.59 1

Page 2 of 5; records 51–100 of 202 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AHMED Z OBEIDAT

NPI 1184069627 · CMS profile ID 1382667

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

MILWAUKEE, WI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 202 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1184069627?year=2019&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AHMED Z OBEIDAT, NPI 1184069627, CMS profile ID 1382667. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 202 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1184069627?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). AHMED Z OBEIDAT, NPI 1184069627, CMS profile ID 1382667. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 202 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1184069627?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
AHMED Z OBEIDAT, NPI 1184069627, CMS profile ID 1382667, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 202 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1184069627?year=2019&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

202 matching records · $211,659.26 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 202 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 202.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Alexion Pharmaceuticals, Inc. $3,045.0010/22/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695624519 CMS
Novartis Pharmaceuticals Corporation $2,350.0010/17/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659756403 CMS
Novartis Pharmaceuticals Corporation $125.0010/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659756407 CMS
Alexion Pharmaceuticals, Inc. $3,045.0010/15/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695624511 CMS
Alexion Pharmaceuticals, Inc. $2,795.0010/15/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695624527 CMS
Alexion Pharmaceuticals, Inc. $3,045.0010/15/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695624545 CMS
Alexion Pharmaceuticals, Inc. $3,045.0010/15/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695624549 CMS
Novartis Pharmaceuticals Corporation $24.3010/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659756397 CMS
Alexion Pharmaceuticals, Inc. $121.8110/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695624433 CMS
Alexion Pharmaceuticals, Inc. $27.6110/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695624441 CMS
Alexion Pharmaceuticals, Inc. $159.8510/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695624445 CMS
Novartis Pharmaceuticals Corporation $2,350.0010/08/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659756391 CMS
Novartis Pharmaceuticals Corporation $105.0010/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659756395 CMS
Alexion Pharmaceuticals, Inc. $192.6610/02/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695624437 CMS
Alexion Pharmaceuticals, Inc. $3,045.0010/01/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695624489 CMS
GENZYME CORPORATION $466.7009/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694262829 CMS
GENZYME CORPORATION $7,785.0009/28/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694263369 CMS
GENZYME CORPORATION $47.8309/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694263371 CMS
GENZYME CORPORATION $69.9909/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694263373 CMS
GENZYME CORPORATION $50.0009/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694263375 CMS
GENZYME CORPORATION $218.6109/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694263377 CMS
GENZYME CORPORATION $344.8509/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694263887 CMS
GENZYME CORPORATION $39.1309/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694329423 CMS
Alexion Pharmaceuticals, Inc. $2,795.0009/26/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695624515 CMS
Biogen, Inc. $3,675.0009/24/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660596231 CMS
Biogen, Inc. $29.4409/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660596233 CMS
Celgene Corporation $124.9809/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672978747 CMS
Biogen, Inc. $150.0009/20/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699344317 CMS
Celgene Corporation $6,820.0009/18/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672863597 CMS
Novartis Pharmaceuticals Corporation $2,820.0009/05/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659756369 CMS
Novartis Pharmaceuticals Corporation $20.4909/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659756371 CMS
Novartis Pharmaceuticals Corporation $140.9009/04/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659756375 CMS
Novartis Pharmaceuticals Corporation $2,654.7509/04/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659756379 CMS
Novartis Pharmaceuticals Corporation $2,820.0009/04/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659756383 CMS
Novartis Pharmaceuticals Corporation $67.2609/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659756387 CMS
Alexion Pharmaceuticals, Inc. $82.5708/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695624385 CMS
Alexion Pharmaceuticals, Inc. $729.1808/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695624389 CMS
Alexion Pharmaceuticals, Inc. $3,045.0008/27/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695624487 CMS
Alexion Pharmaceuticals, Inc. $84.6608/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695624377 CMS
Alexion Pharmaceuticals, Inc. $598.5008/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695624381 CMS
Biogen, Inc. $4,725.0008/21/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660596311 CMS
Biogen, Inc. $47.8808/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660596313 CMS
Alexion Pharmaceuticals, Inc. $3,045.0008/20/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695624483 CMS
Alexion Pharmaceuticals, Inc. $39.8408/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695624370 CMS
Alexion Pharmaceuticals, Inc. $648.3708/15/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695624374 CMS
Alexion Pharmaceuticals, Inc. $3,045.0008/08/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695624495 CMS
Novartis Pharmaceuticals Corporation $14.7308/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659756355 CMS
Novartis Pharmaceuticals Corporation $2,350.0008/06/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659756359 CMS
Novartis Pharmaceuticals Corporation $123.5008/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659756363 CMS
Celgene Corporation $384.6608/02/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672963337 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $211,659.26 202
PY2020 $102,277.61 108
PY2021 $149,156.15 129
PY2022 $249,016.17 229
PY2023 $418,093.31 339
PY2024 $414,842.86 261
PY2025 $339,237.68 238

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,493.40 1
PY2025 Principal investigator $1,436,185.73 133
PY2024 Recipient $2,216.73 9
PY2024 Principal investigator $1,016,038.70 64
PY2023 Recipient $8,730.55 3
PY2023 Principal investigator $755,692.27 62
PY2022 Principal investigator $397,477.77 45
PY2021 Recipient $5,540.28 3
PY2021 Principal investigator $322,116.37 29
PY2020 Recipient $960.00 2
PY2020 Principal investigator $146,054.47 5
PY2019 Recipient $851.48 11

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

134 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GENZYME CORPORATION $19,411.70 12/22/2025 Non-covered Recipient Entity
Medical College Of Wisconsin Inc Att Department Of Medicine Administrati Co Wendy Wozney Medical Col
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226114124
Principal investigator 1 GENZYME CORPORATION $153.75 12/22/2025 Non-covered Recipient Entity
Medical College Of Wisconsin Inc Att Department Of Medicine Administrati Co Wendy Wozney Medical Col
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226114128
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,299.56 12/22/2025 Non-covered Recipient Entity
THE MEDICAL COLLEGE OF WISCONSIN INC
A Pilot Open-Label, Randomized, Multi-Center, Parall el-Arm, of Acute vs Delay Ofatumumab Treatment d uring an Acute Multiple Sclerosis Relapse No dispute reported 06/30/2026 1190303757
Principal investigator 1 Genentech, Inc. $2,231.00 12/19/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211666515
Principal investigator 1 Genentech, Inc. $1,031.00 12/09/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211666444
Principal investigator 1 Genentech, Inc. $4,438.00 12/08/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Phase III study of Satralizumab in AE No dispute reported 06/30/2026 1211666133
Principal investigator 1 Genentech, Inc. $6,215.00 12/04/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Satralizumab in NMOSD patients 100kg No dispute reported 06/30/2026 1211666137
Principal investigator 1 TG Therapeutics, Inc. $7,700.00 11/30/2025 Non-covered Recipient Entity
Froedtert & Medical College of Wisconsin 53226
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226198081
Principal investigator 1 Genentech, Inc. $1,587.00 11/18/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Satralizumab in NMOSD patients 100kg No dispute reported 06/30/2026 1211666128
Principal investigator 1 Genentech, Inc. $750.00 11/18/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211666509
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $74,775.50 11/17/2025 Non-covered Recipient Entity
Medical College Of Wisconsin, Incorporated
A Phase 1, Multicenter, Single-arm, Dose-escalation Study Of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants with Autoimmune Neurological Diseases: Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS), or Refractory Myasthenia Gravis (MG) (Breakfree-2) No dispute reported 06/30/2026 1235995927
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $795.00 11/12/2025 Non-covered Recipient Entity
Medical College Of Wisconsin, Incorporated
A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063) No dispute reported 06/30/2026 1235995929
Principal investigator 1 Genentech, Inc. $537.00 11/05/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Phase III study of Satralizumab in AE No dispute reported 06/30/2026 1211666123
Principal investigator 1 Genentech, Inc. $9,565.00 11/05/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211666500
Principal investigator 1 GENZYME CORPORATION $2,370.00 11/04/2025 Non-covered Recipient Entity
Medical College Of Wisconsin Inc Att Department Of Medicine Administrati Co Wendy Wozney Medical Col
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226114110
Principal investigator 1 GENZYME CORPORATION $6,839.00 11/04/2025 Non-covered Recipient Entity
Medical College Of Wisconsin Inc Att Department Of Medicine Administrati Co Wendy Wozney Medical Col
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226114118
Principal investigator 1 Genentech, Inc. $9,845.00 11/03/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211666399
Principal investigator 1 TG Therapeutics, Inc. $4,512.50 11/01/2025 Non-covered Recipient Entity
Froedtert & Medical College of Wisconsin 53226
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226198073
Principal investigator 1 TG Therapeutics, Inc. $3,700.00 11/01/2025 Non-covered Recipient Entity
Froedtert & Medical College of Wisconsin 53226
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226198079
Principal investigator 1 Genentech, Inc. $46,188.00 10/28/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211666440
Principal investigator 1 TG Therapeutics, Inc. $438.82 10/28/2025 Non-covered Recipient Entity
Froedtert & Medical College of Wisconsin 53226
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226198077
Principal investigator 1 GENZYME CORPORATION $25,122.70 10/27/2025 Non-covered Recipient Entity
Medical College Of Wisconsin Inc Att Department Of Medicine Administrati Co Wendy Wozney Medical Col
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226114091
Principal investigator 1 GENZYME CORPORATION $2,380.00 10/27/2025 Non-covered Recipient Entity
Medical College Of Wisconsin Inc Att Department Of Medicine Administrati Co Wendy Wozney Medical Col
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226114099
Principal investigator 1 GENZYME CORPORATION $1,906.50 10/20/2025 Non-covered Recipient Entity
Interspond LLC
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226148285
Principal investigator 1 GENZYME CORPORATION $695.00 10/20/2025 Non-covered Recipient Entity
Interspond LLC
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226148288
Principal investigator 1 GENZYME CORPORATION $2,000.00 10/20/2025 Non-covered Recipient Entity
Interspond LLC
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226148292
Principal investigator 1 GENZYME CORPORATION $3,000.00 10/20/2025 Non-covered Recipient Entity
Interspond LLC
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226148296
Principal investigator 1 GENZYME CORPORATION $1,441.50 10/20/2025 Non-covered Recipient Entity
Interspond LLC
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226148300
Principal investigator 1 Genentech, Inc. $7,626.00 10/17/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211666494
Principal investigator 1 TG Therapeutics, Inc. $2,687.50 10/17/2025 Non-covered Recipient Entity
Froedtert & Medical College of Wisconsin 53226
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226198075
Principal investigator 1 Genentech, Inc. $2,636.00 10/15/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Phase III study of Satralizumab in AE No dispute reported 06/30/2026 1211666117
Principal investigator 1 Genentech, Inc. $1,566.00 10/15/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211666502
Principal investigator 1 GENZYME CORPORATION $1,159.00 10/14/2025 Non-covered Recipient Entity
Medical College Of Wisconsin Inc Att Department Of Medicine Administrati Co Wendy Wozney Medical Col
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226114105
Principal investigator 1 Novartis Pharmaceuticals Corporation $34,992.47 10/14/2025 Non-covered Recipient Entity
MEDICAL COLLEGE OF WISCONSIN
AGNOS: An 18-month, Open-label, Multi-Center Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Nave, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes No dispute reported 06/30/2026 1190300965
Principal investigator 1 Genentech, Inc. $1,063.00 10/09/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Phase III study of Satralizumab in AE No dispute reported 06/30/2026 1211666120
Principal investigator 1 Genentech, Inc. $3,013.00 10/08/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Satralizumab in NMOSD patients 100kg No dispute reported 06/30/2026 1211666104
Principal investigator 1 Novartis Pharmaceuticals Corporation $128.18 10/08/2025 Non-covered Recipient Entity
MEDICAL COLLEGE OF WISCONSIN
A 2-year Randomized, 3-arm, Double-blind, Non-inferiority Study Comparing the Efficacy and Safety of Ofatumumab and Siponimod Versus Fingolimod in Pediatric Patients With Multiple Sclerosis Followed by an Open-label Extension No dispute reported 06/30/2026 1190300639
Principal investigator 1 Novartis Pharmaceuticals Corporation $903.52 10/07/2025 Covered Recipient Teaching Hospital
Childrens Hospital Of Wisconsin
A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With R No dispute reported 06/30/2026 1190298089
Principal investigator 1 TG Therapeutics, Inc. $2,256.25 09/30/2025 Non-covered Recipient Entity
Froedtert & Medical College of Wisconsin 53226
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226198021
Principal investigator 1 TG Therapeutics, Inc. $600.00 09/30/2025 Non-covered Recipient Entity
Froedtert & Medical College of Wisconsin 53226
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226198035
Principal investigator 1 Genentech, Inc. $2,106.00 09/22/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Phase III study of Satralizumab in AE No dispute reported 06/30/2026 1211666110
Principal investigator 1 TG Therapeutics, Inc. $2,705.00 09/16/2025 Non-covered Recipient Entity
Froedtert & Medical College of Wisconsin 53226
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226198025
Principal investigator 1 GENZYME CORPORATION $26,174.40 09/08/2025 Non-covered Recipient Entity
Medical College Of Wisconsin Inc Att Department Of Medicine Administrati Co Wendy Wozney Medical Col
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226114085
Principal investigator 1 Genentech, Inc. $9,484.00 09/08/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Satralizumab in NMOSD patients 100kg No dispute reported 06/30/2026 1211666107
Principal investigator 1 Genentech, Inc. $2,613.00 09/03/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211666490
Principal investigator 1 Novartis Pharmaceuticals Corporation $423.00 09/01/2025 Non-covered Recipient Entity
MEDICAL COLLEGE OF WISCONSIN
A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With R No dispute reported 06/30/2026 1190306923
Principal investigator 1 Novartis Pharmaceuticals Corporation $46,253.89 08/31/2025 Non-covered Recipient Entity
MEDICAL COLLEGE OF WISCONSIN
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190301057
Principal investigator 1 TG Therapeutics, Inc. $5,906.25 08/31/2025 Non-covered Recipient Entity
Froedtert & Medical College of Wisconsin 53226
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226198019
Principal investigator 1 TG Therapeutics, Inc. $1,650.00 08/31/2025 Non-covered Recipient Entity
Froedtert & Medical College of Wisconsin 53226
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226198033
Principal investigator 1 Genentech, Inc. $9,416.00 08/26/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211666431
Principal investigator 1 GENZYME CORPORATION $3,606.00 08/25/2025 Non-covered Recipient Entity
Medical College Of Wisconsin Inc Att Department Of Medicine Administrati Co Wendy Wozney Medical Col
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226114080
Principal investigator 1 Genentech, Inc. $8,390.00 08/20/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211666435
Principal investigator 1 Genentech, Inc. $631.00 08/08/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Phase III study of Satralizumab in AE No dispute reported 06/30/2026 1211666113
Principal investigator 1 TG Therapeutics, Inc. $3,437.25 07/31/2025 Non-covered Recipient Entity
Froedtert & Medical College of Wisconsin 53226
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226198017
Principal investigator 1 TG Therapeutics, Inc. $11,750.00 07/31/2025 Non-covered Recipient Entity
Froedtert & Medical College of Wisconsin 53226
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226198031
Principal investigator 1 Genentech, Inc. $1,150.00 07/29/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Satralizumab in NMOSD patients 100kg No dispute reported 06/30/2026 1211666098
Principal investigator 1 Genentech, Inc. $9,565.00 07/29/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211666485
Principal investigator 1 Genentech, Inc. $6,418.75 07/25/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Satralizumab in MOG AD No dispute reported 06/30/2026 1211666388
Principal investigator 1 TG Therapeutics, Inc. $2,625.00 07/24/2025 Non-covered Recipient Entity
Froedtert & Medical College of Wisconsin 53226
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226198023
Principal investigator 1 Genentech, Inc. $13,882.00 07/21/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211666425
Principal investigator 1 Genentech, Inc. $2,231.00 07/21/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211666478
Principal investigator 1 EMD Serono, Inc. $750.00 07/16/2025 Non-covered Recipient Entity
THE MEDICAL COLLEGE OF WISCONSIN INC
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118555
Principal investigator 1 GENZYME CORPORATION $6,252.00 07/14/2025 Non-covered Recipient Entity
Medical College Of Wisconsin Inc Att Department Of Medicine Administrati Co Wendy Wozney Medical Col
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226114076
Principal investigator 1 Genentech, Inc. $5,695.00 07/10/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Phase III study of Satralizumab in AE No dispute reported 06/30/2026 1211666101
Principal investigator 1 Genentech, Inc. $324.00 07/10/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211666429
Principal investigator 1 Genentech, Inc. $938.00 07/09/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211666480
Principal investigator 1 TG Therapeutics, Inc. $2,500.00 06/30/2025 Non-covered Recipient Entity
Froedtert & Medical College of Wisconsin 53226
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226197957
Principal investigator 1 Genentech, Inc. $4,815.00 06/25/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211666462
Principal investigator 1 EMD Serono, Inc. $83.00 06/24/2025 Non-covered Recipient Entity
THE MEDICAL COLLEGE OF WISCONSIN INC
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118541
Principal investigator 1 EMD Serono, Inc. $750.00 06/24/2025 Non-covered Recipient Entity
THE MEDICAL COLLEGE OF WISCONSIN INC
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118543
Principal investigator 1 EMD Serono, Inc. $9,000.00 06/24/2025 Non-covered Recipient Entity
THE MEDICAL COLLEGE OF WISCONSIN INC
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118545
Principal investigator 1 EMD Serono, Inc. $1,875.00 06/24/2025 Non-covered Recipient Entity
THE MEDICAL COLLEGE OF WISCONSIN INC
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118547
Principal investigator 1 EMD Serono, Inc. $1,875.00 06/24/2025 Non-covered Recipient Entity
THE MEDICAL COLLEGE OF WISCONSIN INC
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118549
Principal investigator 1 EMD Serono, Inc. $1,250.00 06/24/2025 Non-covered Recipient Entity
THE MEDICAL COLLEGE OF WISCONSIN INC
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118551
Principal investigator 1 EMD Serono, Inc. $125.00 06/24/2025 Non-covered Recipient Entity
THE MEDICAL COLLEGE OF WISCONSIN INC
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118553
Principal investigator 1 Genentech, Inc. $2,231.00 06/24/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211666460
Principal investigator 1 Novartis Pharmaceuticals Corporation $12,500.00 06/24/2025 Non-covered Recipient Entity
THE MEDICAL COLLEGE OF WISCONSIN
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190300465
Principal investigator 1 Genentech, Inc. $1,956.00 06/20/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211666395
Principal investigator 1 Celgene Corporation $15,623.00 06/16/2025 Non-covered Recipient Entity
Medical College Of Wisconsin Emergency Medicine
A Phase 1, Multicenter, Single-arm, Dose-escalation Study Of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants with Autoimmune Neurological Diseases: Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS), or Refractory Myasthenia Gravis (MG) (Breakfree-2) No dispute reported 06/30/2026 1222306519
Principal investigator 1 Genentech, Inc. $937.50 06/04/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Satralizumab in MOG AD No dispute reported 06/30/2026 1211666372
Principal investigator 1 TG Therapeutics, Inc. $5,615.00 06/01/2025 Non-covered Recipient Entity
Froedtert & Medical College of Wisconsin 53226
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226197955
Principal investigator 1 TG Therapeutics, Inc. $4,835.00 05/29/2025 Non-covered Recipient Entity
Froedtert & Medical College of Wisconsin 53226
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226197953
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,412.38 05/27/2025 Non-covered Recipient Entity
Medical College Of Wisconsin
A Phase 1, Multicenter, Single-arm, Dose-escalation Study Of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants with Autoimmune Neurological Diseases: Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS), or Refractory Myasthenia Gravis (MG) (Breakfree-2) No dispute reported 06/30/2026 1235995943
Principal investigator 1 GENZYME CORPORATION $9,059.20 05/27/2025 Non-covered Recipient Entity
Medical College Of Wisconsin Inc Att Department Of Medicine Administrati Co Wendy Wozney Medical Col
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226114071
Principal investigator 1 Genentech, Inc. $18,222.00 05/27/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Satralizumab in NMOSD patients 100kg No dispute reported 06/30/2026 1211666060
Principal investigator 1 Celgene Corporation $2,550.00 05/21/2025 Non-covered Recipient Entity
Medical College Of Wisconsin Emergency Medicine
A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063) No dispute reported 06/30/2026 1222306461
Principal investigator 1 Genentech, Inc. $2,824.00 05/20/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Phase III study of Satralizumab in AE No dispute reported 06/30/2026 1211666074
Principal investigator 1 Genentech, Inc. $1,574.00 05/20/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Satralizumab in NMOSD patients 100kg No dispute reported 06/30/2026 1211666081
Principal investigator 1 Genentech, Inc. $11,171.76 05/13/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211666417
Principal investigator 1 TG Therapeutics, Inc. $6,404.64 05/12/2025 Non-covered Recipient Entity
Froedtert & Medical College of Wisconsin 53226
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226197993
Principal investigator 1 Genentech, Inc. $10,037.00 05/09/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Satralizumab in MOG AD No dispute reported 06/30/2026 1211666384
Principal investigator 1 Genentech, Inc. $30,662.00 05/09/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211666421
Principal investigator 1 GENZYME CORPORATION $35,157.40 05/05/2025 Non-covered Recipient Entity
Medical College Of Wisconsin Inc Att Department Of Medicine Administrati Co Wendy Wozney Medical Col
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226114060
Principal investigator 1 Amgen Inc. $53,863.50 05/02/2025 Non-covered Recipient Entity
MEDICAL COLLEGE OF WISCONSIN INC
A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety Between ABP 692 and Ocrevus (Ocrelizumab) in Subjects With Relapsing-remitting Multiple Sclerosis No dispute reported 06/30/2026 1246644142
Principal investigator 1 TG Therapeutics, Inc. $6,850.00 05/01/2025 Non-covered Recipient Entity
Froedtert & Medical College of Wisconsin 53226
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226197951
Principal investigator 1 Genentech, Inc. $1,565.00 04/28/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211666472
Principal investigator 1 Genentech, Inc. $1,672.00 04/22/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Satralizumab in NMOSD patients 100kg No dispute reported 06/30/2026 1211666078
Principal investigator 1 Genentech, Inc. $6,938.00 04/15/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Phase III study of Satralizumab in AE No dispute reported 06/30/2026 1211666095
Principal investigator 1 Alexion Pharmaceuticals, Inc. $8,166.00 04/14/2025 Non-covered Recipient Entity
MEDICAL COLLEGE OF WISCONSIN MEDICAL SCHOOL
A Long-Term, Prospective, Observational, Registry of Patients with Anti-Aquaporin 4 Antibody-Positive (AQP4+) Neuromyelitis Optica Spectrum Disorder (NMOSD) Treated with Alexion Complement Component 5 (C5) Inhibitor Therapies (ALXN-C5IT) No dispute reported 06/30/2026 1185543472
Principal investigator 1 Genentech, Inc. $937.50 04/14/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Satralizumab in MOG AD No dispute reported 06/30/2026 1211666380
Principal investigator 1 TG Therapeutics, Inc. $106.25 04/14/2025 Non-covered Recipient Entity
Froedtert & Medical College of Wisconsin 53226
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226197947
Principal investigator 1 TG Therapeutics, Inc. $17,570.00 04/14/2025 Non-covered Recipient Entity
Froedtert & Medical College of Wisconsin 53226
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226197949
Principal investigator 1 Celgene Corporation $750.00 04/09/2025 Non-covered Recipient Entity
Clinical And Translational Science Institute
Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)- or No Disease Modifying Therapy No dispute reported 06/30/2026 1222307183
Principal investigator 1 Celgene Corporation $4,833.33 04/09/2025 Non-covered Recipient Entity
Clinical And Translational Science Institute
A PHASE 3B, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE IMMUNOLOGICAL RESPONSE TO, AND THE SAFETY OF, THREE PARENTERALLY ADMINISTERED VACCINES IN SUBJECTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS WHO RECEIVE ORAL OZANIMOD, NON-PEGYLATED INTERFERON-, OR NO DISEASE MODIFYING THERAPY No dispute reported 06/30/2026 1222307199
Recipient F. Hoffmann-La Roche AG $2,493.40 03/31/2025 Covered Recipient Physician Switch From Eculizumab to Satralizumab in Aquaporin 4 Immunoglobulin G–Seropositive Neuromyelitis Optica Spectrum Disorder: A Case Series Report No dispute reported 06/30/2026 1211534241
Principal investigator 1 Genentech, Inc. $614.00 03/26/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Phase III study of Satralizumab in AE No dispute reported 06/30/2026 1211666086
Principal investigator 1 Genentech, Inc. $2,082.00 03/21/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211666475
Principal investigator 1 Genentech, Inc. $7,188.00 03/20/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Phase III study of Satralizumab in AE No dispute reported 06/30/2026 1211666090
Principal investigator 1 Genentech, Inc. $9,505.00 03/20/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211666412
Principal investigator 1 TG Therapeutics, Inc. $5,337.20 03/18/2025 Non-covered Recipient Entity
Froedtert & Medical College of Wisconsin 53226
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226197989
Principal investigator 1 Genentech, Inc. $9,000.00 03/10/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211666393
Principal investigator 1 GENZYME CORPORATION $3,723.00 03/04/2025 Non-covered Recipient Entity
Medical College Of Wisconsin Inc Att Department Of Medicine Administrati Co Wendy Wozney Medical Col
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226114033
Principal investigator 1 GENZYME CORPORATION $7,503.00 03/04/2025 Non-covered Recipient Entity
Medical College Of Wisconsin Inc Att Department Of Medicine Administrati Co Wendy Wozney Medical Col
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226114041
Principal investigator 1 GENZYME CORPORATION $10,534.70 03/04/2025 Non-covered Recipient Entity
Medical College Of Wisconsin Inc Att Department Of Medicine Administrati Co Wendy Wozney Medical Col
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226114047
Principal investigator 1 EMD Serono, Inc. $125.00 03/03/2025 Non-covered Recipient Entity
THE MEDICAL COLLEGE OF WISCONSIN INC
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118535
Principal investigator 1 EMD Serono, Inc. $1,250.00 03/03/2025 Non-covered Recipient Entity
THE MEDICAL COLLEGE OF WISCONSIN INC
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118537
Principal investigator 1 EMD Serono, Inc. $325.00 03/03/2025 Non-covered Recipient Entity
THE MEDICAL COLLEGE OF WISCONSIN INC
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118539
Principal investigator 1 Genentech, Inc. $6,539.00 02/20/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Satralizumab in NMOSD patients 100kg No dispute reported 06/30/2026 1211666063
Principal investigator 1 Novartis Pharmaceuticals Corporation $240,136.73 02/19/2025 Non-covered Recipient Entity
THE MEDICAL COLLEGE OF WISCONSIN INC
A Pilot Open-Label, Randomized, Multi-Center, Parall el-Arm, of Acute vs Delay Ofatumumab Treatment d uring an Acute Multiple Sclerosis Relapse No dispute reported 06/30/2026 1190307681
Principal investigator 1 Genentech, Inc. $1,565.00 02/18/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211666466
Principal investigator 1 Genentech, Inc. $20,079.00 02/14/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211666407
Principal investigator 1 Genentech, Inc. $17,428.00 02/13/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211666403
Principal investigator 1 Genentech, Inc. $9,272.00 02/12/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Satralizumab in NMOSD patients 100kg No dispute reported 06/30/2026 1211666070
Principal investigator 1 TG Therapeutics, Inc. $2,637.50 02/11/2025 Non-covered Recipient Entity
Froedtert & Medical College of Wisconsin 53226
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226197945
Principal investigator 1 Genentech, Inc. $15,336.50 02/04/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Satralizumab in MOG AD No dispute reported 06/30/2026 1211666377
Principal investigator 1 Novartis Pharmaceuticals Corporation $68,107.46 02/04/2025 Non-covered Recipient Entity
THE MEDICAL COLLEGE OF WISCONSIN
A 2-year Randomized, 3-arm, Double-blind, Non-inferiority Study Comparing the Efficacy and Safety of Ofatumumab and Siponimod Versus Fingolimod in Pediatric Patients With Multiple Sclerosis Followed by an Open-label Extension No dispute reported 06/30/2026 1190300461
Principal investigator 1 TG Therapeutics, Inc. $3,202.32 02/03/2025 Non-covered Recipient Entity
Froedtert & Medical College of Wisconsin 53226
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226197987
Principal investigator 1 Alexion Pharmaceuticals, Inc. $1,440.50 01/22/2025 Non-covered Recipient Entity
MEDICAL COLLEGE OF WISCONSIN EMERGENCY MEDICINE
A Long-Term, Prospective, Observational, Registry of Patients with Anti-Aquaporin 4 Antibody-Positive (AQP4+) Neuromyelitis Optica Spectrum Disorder (NMOSD) Treated with Alexion Complement Component 5 (C5) Inhibitor Therapies (ALXN-C5IT) No dispute reported 06/30/2026 1185543470
Principal investigator 1 GENZYME CORPORATION $36,740.00 01/21/2025 Non-covered Recipient Entity
Medical College Of Wisconsin Inc Att Department Of Medicine Administrati Co Wendy Wozney Medical Col
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226114054
Principal investigator 1 Genentech, Inc. $2,231.00 01/17/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211666468
Principal investigator 1 Novartis Pharmaceuticals Corporation $92,624.22 01/14/2025 Non-covered Recipient Entity
MEDICAL COLLEGE OF WISCONSIN
AGNOS: An 18-month, Open-label, Multi-Center Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Nave, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes No dispute reported 06/30/2026 1190300967
Principal investigator 1 Genentech, Inc. $625.00 01/08/2025 Non-covered Recipient Entity
The Medical College of Wisconsin, Inc.
Phase III study of Satralizumab in AE No dispute reported 06/30/2026 1211666066
Principal investigator 1 GENZYME CORPORATION $36,740.00 01/06/2025 Non-covered Recipient Entity
Medical College Of Wisconsin Inc Att Department Of Medicine Administrati Co Wendy Wozney Medical Col
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226114065
Principal investigator 1 Novartis Pharmaceuticals Corporation $39,062.15 01/01/2025 Non-covered Recipient Entity
MEDICAL COLLEGE OF WISCONSIN
A 2-year Randomized, 3-arm, Double-blind, Non-inferiority Study Comparing the Efficacy and Safety of Ofatumumab and Siponimod Versus Fingolimod in Pediatric Patients With Multiple Sclerosis Followed by an Open-label Extension No dispute reported 06/30/2026 1190300641